Abstract
Hospital-acquired Clostridium difficile infections have become much more frequent in recent years. Besides treatment with antibiotics and fecal microbiota transplant, new preventive strategies are available now. Bezlotoxumab is an antibody against toxin B and may reduce the risk of relapse by roughly 10 %. Several vaccine candidates against toxins A and B and surface-associated antigens were immunogenic and are tested in clinical trials to investigate the efficacy and safety.
© Georg Thieme Verlag KG Stuttgart · New York.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Neutralizing / therapeutic use*
-
Bacterial Vaccines / therapeutic use*
-
Broadly Neutralizing Antibodies
-
Clostridioides difficile / immunology
-
Clostridium Infections* / immunology
-
Clostridium Infections* / microbiology
-
Clostridium Infections* / prevention & control
-
Clostridium Infections* / therapy
-
Fecal Microbiota Transplantation
-
Humans
-
Middle Aged
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Antibodies, Neutralizing
-
Bacterial Vaccines
-
Broadly Neutralizing Antibodies
-
bezlotoxumab